$ALVO earnings report

Alvotech 9M 2026 adjusted total revenue fell 23.0% to $323.4 million while 3Q adjusted EBITDA rose 118.8%; full-year 2026 guidance maintained with performance now expected toward the lower end of the range. AlphAI read Alvotech's 9M 2026 (nine months to September 30, 2026) filing as mixed. 2 quarters are on record below.

9M 2026 (nine months to September 30, 2026)

AlphAI · Earnings readALVO · 9M 2026 (nine months to September 30, 2026) · ended 2026-09-30

Alvotech 9M 2026 adjusted total revenue fell 23.0% to $323.4 million while 3Q adjusted EBITDA rose 118.8%; full-year 2026 guidance maintained with performance now expected toward the lower end of the range

→Mixed quarter

Nine-month adjusted revenue fell 23.0% and License and Other Revenue fell 12.9%, but third-quarter product and service revenue rose 78.3% year over year and adjusted EBITDA rose 118.8% in the quarter. Reported nine-month net loss was $(140,659) thousand against a prior-year profit of $136,466 thousand, cash fell to $61.5 million, and management now expects performance toward the lower end of the full-year range.

Revenue
$323M
-23.0% y/y
Product and service revenue
$164.2 million (9M 2026, adjusted); $58.2 million (3Q 2026, adjusted)
-30.8% (9M); 78.3% (3Q) y/y · 6% (3Q, per CEO statement) q/q
Gross margin · non-GAAP
54%
EPS · GAAP
$(0.45)
Full year 2026 outlook
$650-$700 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenue, 9M 2026 (adjusted)non-GAAP$323.4M–-23.0%
Product and service revenue, 9M 2026 (adjusted)non-GAAP$164.2M–-30.8%
License and other revenue, 9M 2026 (adjusted)non-GAAP$158.9M–-12.9%
Gross margin, 9M 2026 (adjusted)non-GAAP54%––
Adjusted EBITDA, 9M 2026non-GAAP$78.3M–15.1%
Adjusted operating profit, 9M 2026non-GAAP$46.3M––
Reported (IFRS) operating profit, 9M 2026GAAP$10.78M––
Reported (IFRS) EBITDA, 9M 2026GAAP$42.8M––
Finance costs, 9M 2026 (IFRS)GAAP−$168.7M––
Income tax benefit, 9M 2026 (IFRS)GAAP$13.55M––
(Loss) / profit for the period, 9M 2026 (IFRS)GAAP−$140.7M––
Basic and diluted (loss) / profit per share, 9M 2026 (IFRS)GAAP$(0.45) per share––
Net cash (used in) / from operating activities, 9M 2026 (IFRS)GAAP−$205.6M––
Cash and cash equivalents at September 30, 2026 (vs December 31, 2025)other$61.5M––
Total revenue, 3Q 2026 (adjusted)non-GAAP$111.6M–-2.0%
Product and service revenue, 3Q 2026 (adjusted)non-GAAP$58.2M6%78.3%
License and other revenue, 3Q 2026 (adjusted)non-GAAP$53.2M–-34.4%
Gross margin, 3Q 2026 (adjusted)non-GAAP54%––
Adjusted EBITDA, 3Q 2026non-GAAP$31.5M–118.8%
Adjusted operating profit, 3Q 2026non-GAAP$20.1M––
Reported (IFRS) EBITDA, 3Q 2026GAAP$24.2M––

Segments

SegmentRevenueq/qy/y
Product and service revenueThe company states that following the completion of the manufacturing improvement program in the first half of the year, it is continuing to increase supply to meet strong underlying demand across its markets. The CEO states product and service revenue reached $58 million in the third quarter.$164.2 million (9M 2026, adjusted); $58.2 million (3Q 2026, adjusted)6% (3Q, per CEO statement)-30.8% (9M); 78.3% (3Q)
License and other revenueThe filing prints the revenue lines and their changes but does not state a driver for this line. The company reports the Lotus Pharmaceuticals agreement for AVT34 and AVT87 commercialization rights in the U.S. and selected Asian markets.$158.9 million (9M 2026, adjusted); $53.2 million (3Q 2026, adjusted)–-12.9% (9M); -34.4% (3Q)

Full year 2026 outlook

  • Revenue$650-$700 million
  • NoteEBITDA $180-$220 million
  • NoteGuidance maintained; performance now expected toward the lower end of the range (company statement)
  • NoteCompany focus on executing planned product deliveries in the fourth quarter as production and commercial supply ramp up after the manufacturing improvement program completed in the first half

Capital returns

  • No share repurchase or dividend line appears in the filing.
  • Gross proceeds from equity offering: 164,600 thousand (9M 2026) versus 82,481 thousand (9M 2025); fees from equity offering (8,521) thousand versus (3,759) thousand.

What drove it

  • The company states that the FDA approved a new Simlandi manufacturing process at the Reykjavik facility that more than doubles output per batch, and approved a second production suite for Simlandi drug substance at the same site.
  • The company states that production and commercial supply continue to ramp up following the manufacturing improvement program completed in the first half of 2026.
  • The FDA accepted the BLA for AVT80, a proposed biosimilar to Entyvio (vedolizumab), in prefilled syringe and autoinjector presentations. Teva has licensed U.S. commercial rights.
  • Alvotech and Advanz Pharma submitted the first known regulatory submission worldwide for a proposed biosimilar to Eylea HD (aflibercept 8 mg) to the European Medicines Agency.
  • Agreement with Lotus Pharmaceuticals covers U.S. and selected Asian commercialization rights for AVT34 (Imfinzi biosimilar) and AVT87 (Hemlibra biosimilar); Alvotech retains the right to also commercialize directly in the U.S.
  • LOTTE Biologics will manufacture drug substance for multiple biosimilars at its Syracuse, New York facility, which the company says expands its U.S. manufacturing footprint.

Concerns

  • Nine-month adjusted total revenue fell 23.0% year over year, with License and Other Revenue down 12.9% and third-quarter License and Other Revenue down 34.4%.
  • Nine-month reported (loss) / profit for the period was $(140,659) thousand against $136,466 thousand a year earlier, with finance costs of $(168,684) thousand.
  • Net cash used in operating activities was $(205,612) thousand for 9M 2026, and cash fell to $61.5 million from $172.4 million at December 31, 2025.
  • Total equity was negative at $(267,267) thousand at September 30, 2026.
  • Management now expects performance toward the lower end of the full-year 2026 revenue ($650-$700 million) and EBITDA ($180-$220 million) ranges, and the filing does not provide a quarterly breakdown needed to test the guidance.

What to watch

  • Delivery of planned product volumes in the fourth quarter of 2026, as stated by the company.
  • Whether full-year 2026 revenue and EBITDA land in the lower part of the $650-$700 million and $180-$220 million ranges.
  • Cash position of $61.5 million at September 30, 2026 against $(205,612) thousand of 9M operating cash outflow.
  • Progress of the FDA review of the AVT80 BLA and the EMA review of the proposed Eylea HD biosimilar; the filing gives no decision dates.
  • Commercial execution under the Lotus agreement for AVT34 and AVT87.
  • Q4 2026 results release scheduled for March 10, 2027, with the earnings call on March 11, 2027.

Balance sheet and cash flow

  • Total assets: $1,616,043 thousand at September 30, 2026 versus $1,487,099 thousand at December 31, 2025.
  • Total equity: $(267,267) thousand at September 30, 2026 versus $(284,487) thousand at December 31, 2025.
  • Borrowings (non-current): $1,341,286 thousand versus $1,262,147 thousand at December 31, 2025. Current maturities of borrowings: $54,967 thousand versus $36,921 thousand.
  • Derivative financial liabilities (non-current): $90,540 thousand versus $53,994 thousand at December 31, 2025.
  • Inventories: $242,252 thousand versus $220,054 thousand at December 31, 2025.
  • Cash used in operations before interest and tax, 9M 2026: $(96,611) thousand versus $35,215 thousand in 9M 2025.
  • Interest paid, 9M 2026: $(109,061) thousand versus $(22,338) thousand in 9M 2025.
  • Net cash used in investing activities, 9M 2026: $(128,521) thousand versus $(88,449) thousand in 9M 2025; acquisition of intangible assets $(88,164) thousand versus $(24,632) thousand.
  • Net cash from financing activities, 9M 2026: $224,085 thousand versus $64,063 thousand in 9M 2025.
  • Decrease in cash and cash equivalents, 9M 2026: $(110,048) thousand; cash at end of period $61,468 thousand.

Analysis

Alvotech reported nine-month 2026 adjusted total revenue of $323.4 million, down 23.0% from $420.0 million, with product and service revenue down 30.8% and License and Other Revenue down 12.9%. Gross margin on the adjusted basis was 54% against 59% a year earlier. Third-quarter adjusted total revenue was $111.6 million, down 2.0% year over year, but within that the product and service line rose 78.3% to $58.2 million while License and Other Revenue fell 34.4% to $53.2 million. The mix shift is visible in the quarter: product revenue is the line the company describes as recovering after the manufacturing improvement program completed in the first half, while license revenue fell from $81.1 million a year earlier.

Profitability on the adjusted measures improved in the quarter. Adjusted EBITDA was $31.5 million in 3Q 2026 against $14.4 million, and $78.3 million for nine months against $68.0 million, up 15.1%. Third-quarter gross margin was 54% against 69% a year earlier. On the IFRS basis, nine-month operating profit was $10,779 thousand against $29,952 thousand, and nine-month reported EBITDA was $42.8 million against $57.4 million. The reported loss for the nine months was $(140,659) thousand against a profit of $136,466 thousand, with finance costs of $(168,684) thousand against $(108,449) thousand and an income tax benefit of $13,546 thousand against $39,822 thousand. Basic and diluted per-share result was $(0.45) against $0.47. The filing does not reconcile the gap between adjusted operating profit and the reported loss below the operating line beyond the line items printed.

Cash and balance sheet figures show the pressure. Cash and cash equivalents were $61.5 million at September 30, 2026 against $172.4 million at December 31, 2025. Net cash used in operating activities was $(205,612) thousand for nine months, with interest paid of $(109,061) thousand. Investing outflows of $(128,521) thousand included $(88,164) thousand for intangible assets, and financing inflows of $224,085 thousand included $164,600 thousand of gross equity offering proceeds and $113,676 thousand of new borrowings. Total equity was $(267,267) thousand and total borrowings were $1,341,286 thousand non-current plus $54,967 thousand current, reported as separate lines. No share repurchases or dividends appear in the filing.

Management maintained full-year 2026 guidance for total revenue of $650-$700 million and EBITDA of $180-$220 million, and said performance is now expected toward the lower end of the range. The filing does not provide a prior-quarter revenue figure, a quarterly cash flow or a gross margin guide, so the arithmetic required to test the guide is left to the reader. Operationally, the company reports FDA acceptance of the AVT80 BLA, an EMA submission for a proposed Eylea HD biosimilar, a Lotus licensing agreement for AVT34 and AVT87, a LOTTE Biologics manufacturing partnership, and two FDA approvals for Simlandi at Reykjavik, including a process that more than doubles output per batch. The company states its priority is planned product deliveries in the fourth quarter.

Management, verbatim

Our commercial performance strengthened in the third quarter, with product and service revenue reaching $58 million, up 6% sequentially and 78% year over year.

Lisa Graver, Chief Executive Officer

Not in the filing

stated, not guessed
  • Full-year 2026 gross margin, operating expense and tax rate guidance are not printed.
  • Prior-quarter (2Q 2026) figures are not printed, so qoq_change is null except where the CEO statement gives a sequential change for product and service revenue.
  • Gross margin change in percentage points is not printed for 9M or 3Q.
  • Reported (IFRS) operating profit and EBITDA for 3Q 2025 and the 3Q 2026 reported operating profit are only partly printed; the 3Q reported operating profit of 12.8 and prior 1.3 millions are on the reconciliation table only and were not used as key metrics.
  • License and other revenue 9M 2025 is 182.4 in the Financial Highlights table but 182.6 adjusted in the reconciliation table; the highlights figure was used and the difference is not explained in the filing.
  • Cash at September 30, 2025 (42,848 thousand per the cash flow statement) is printed but the prior-year balance sheet date is not a comparable comparative in the highlights; not used as prior_year.
  • Free cash flow is not printed and was not computed.
  • Share price reaction, consensus estimates and analyst expectations are not in the documents.
  • Adjusted net income or adjusted EPS are not printed.
  • Quarterly 3Q 2026 IFRS net loss and EPS are not printed.
  • Dates of FDA and EMA decisions are not printed.
  • Driver of the 3Q 2026 License and Other Revenue decline is not stated in the filing.
  • The previous outlook covered the full year 2026 only, so there is nothing to compare for the nine months ended September 30, 2026.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

H1 2026

AlphAI · Earnings readALVO · H1 2026

Alvotech reported H1 2026 adjusted total revenue of $211.9 million and adjusted EBITDA of $46.9 million, while maintaining 2026 guidance for total revenues of $650-$700 million and adjusted EBITDA of $180-220 million.

→Mixed half-year

Revenue and adjusted EBITDA declined year over year as the manufacturing improvement program reduced output and product availability, while gross margin remained broadly level and the company cited restored planned operating levels, confirmed demand, regulatory progress and new financing.

Revenue
$212M
-30.8% y/y
Product and Service Revenue
$106M
-48.3% y/y
Gross margin · non-GAAP
54%
2026 full year outlook
$650-$700 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Product and Service Revenuenon-GAAP$105.9M–-48.3%
License and Other Revenuenon-GAAP$105.7M–4.4%
Other Incomenon-GAAP$200K–49.7%
Total revenuenon-GAAP$211.9M–-30.8%
Gross marginnon-GAAP54%––
Adjusted EBITDAnon-GAAP$46.9M–-12.7%
Cash-balance at the end of the periodother$142.8M––

Segments

SegmentRevenueq/qy/y
Product and Service RevenueThe manufacturing improvement program affected output and product availability during the first half.$105.9M–-48.3%
License and Other RevenueNo specific revenue driver was reported.$105.7M–4.4%

2026 full year outlook

  • Revenue$650-$700 million
  • NoteAdjusted EBITDA: $180-220 million

What drove it

  • Manufacturing returned to planned operating levels at the end of the second quarter.
  • The company is building supply to meet confirmed demand.
  • Underlying commercial demand for products remains strong, both in the U.S. and Europe.
  • Five biosimilars are now contributing to product revenue.
  • FDA confirmed review completion goal dates for AVT05, AVT06 and AVT03 in alignment with the standard 6-month process, with decisions anticipated in the fourth quarter of 2026.
  • FDA closed its inspection of the Reykjavik manufacturing facility and confirmed a VAI classification.

Concerns

  • Product and Service Revenue declined -48.3% year over year to $105.9 million.
  • Adjusted total revenue declined -30.8% year over year to $211.9 million.
  • Adjusted EBITDA declined -12.7% year over year to $46.9 million.
  • The manufacturing improvement program affected output and product availability during the first half.
  • Cash-balance at the end of the period was $142.8 million, compared to $172.4 million on December 31, 2025.

What to watch

  • FDA decisions for AVT05, AVT06 and AVT03 anticipated in the fourth quarter of 2026.
  • Whether manufacturing output and supply building support strengthening financial performance through the second half of the year.
  • Progress toward 2026 total revenues of $650-$700 million and adjusted EBITDA of $180-220 million.
  • FDA acceptance of the AVT16 BLA and EMA validation of the European applications for AVT16 and AVT80.

Balance sheet and cash flow

  • Cash-balance at the end of the period was $142.8 million compared to $172.4 million on December 31, 2025.
  • Alvotech closed an underwritten public offering and private placement, generating gross proceeds of approximately $165 million.
  • Liquidity was further strengthened by a new term loan facility of $75 million with funds managed by GoldenTree Asset Management LP.

Analysis

Alvotech reported adjusted total revenue of $211.9 million for H1 2026, compared to $306.1 million in the same period last year, a -30.8% change. The principal pressure was Product and Service Revenue, which declined -48.3% to $105.9 million. License and Other Revenue increased 4.4% to $105.7 million, making it a substantially larger reported component of adjusted revenue than product and service revenue in the period.

Management attributed the first-half revenue and adjusted EBITDA outcome to its manufacturing improvement program, which affected output and product availability. Adjusted EBITDA was $46.9 million, compared to $53.7 million in H1 2025, while gross margin was 54% versus 55%. The broadly level gross margin indicates that the reported operational disruption coincided with lower revenue and EBITDA without a material reported change in gross-margin percentage.

Management said manufacturing returned to planned operating levels at the end of the second quarter and that the company is building supply to meet confirmed demand. It also stated that underlying commercial demand remains strong in the U.S. and Europe, with five biosimilars contributing to product revenue. The key execution issue for the second half is whether resumed manufacturing output and supply availability translate into the strengthening financial performance management expects.

The company reported a cash-balance of $142.8 million at period end, compared to $172.4 million on December 31, 2025. During the period, it closed an underwritten public offering and private placement that generated gross proceeds of approximately $165 million and established a new $75 million term loan facility. The stated uses of the equity proceeds are continued pipeline development, working capital and general corporate purposes.

Regulatory progress remains an important catalyst. Alvotech resubmitted U.S. applications for AVT05 and AVT06, while Dr. Reddy’s Laboratories resubmitted AVT03; FDA decisions are anticipated in the fourth quarter of 2026. Management maintained 2026 full-year total-revenue guidance of $650-$700 million and adjusted EBITDA guidance of $180-220 million. The release provides no prior outlook for comparison, so there is no reported basis to assess changes from prior guidance.

Management, verbatim

The manufacturing improvement program affected output and product availability during the first half, which was reflected in our revenues and adjusted EBITDA.

Lisa Graver, CEO

Manufacturing returned to planned operating levels at the end of the second quarter, and we are building supply to meet confirmed demand.

Lisa Graver, CEO

Importantly, underlying commercial demand for products remains strong, both in the U.S. and Europe.

Lisa Graver, CEO

Not in the filing

stated, not guessed
  • Period-end date for H1 2026.
  • IFRS revenue, gross profit, operating income, net income and earnings per share.
  • GAAP or IFRS reconciliation for adjusted total revenue, gross margin and adjusted EBITDA.
  • Operating cash flow and free cash flow.
  • Debt balance, maturity, interest rate and amounts drawn under the new term loan facility.
  • Share repurchases, dividends or other capital-return figures.
  • Quarterly Q2 2026 financial results.
  • Prior-quarter comparisons for reported financial metrics.
  • Full-year 2026 guidance for gross margin, operating expenses and tax rate.
  • Prior guidance or previous outlook for comparison.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about ALVO earnings dates

When is Alvotech's next earnings date?
AlphAI has no date for ALVO yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.